TABLE OF CONTENTS
1 INTRODUCTION 39
1.1 OBJECTIVES OF THE STUDY 39
1.2 MARKET DEFINITION 39
1.3 OVERVIEW OF THE EUROPE OPHTHALMOLOGY LASERS MARKET 39
1.4 CURRENCY AND PRICING 41
1.5 LIMITATIONS 41
1.6 MARKETS COVERED 41
2 EUROPE OPHTHALMOLOGY LASERS MARKET: SEGMENTATION 44
2.1 MARKETS COVERED 44
2.2 GEOGRAPHICAL SCOPE 45
2.3 YEARS CONSIDERED FOR THE STUDY 46
2.4 DBMR TRIPOD DATA VALIDATION MODEL 47
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 50
2.6 MULTIVARIATE MODELLING 51
2.7 PRODUCT LIFELINE CURVE 51
2.8 DBMR MARKET POSITION GRID 52
2.9 VENDOR SHARE ANALYSIS 54
2.10 MARKET END USER COVERAGE GRID 55
2.11 SECONDARY SOURCES 56
3 EXECUTIVE SUMMARY 57
4 PREMIUM INSIGHTS 59
4.1 PORTERS FIVE FORCES 60
4.2 PESTEL ANALYSIS 61
4.3 STRATEGIC INITIATIVES 62
5 EUROPE OPHTHALMOLOGY LASERS MARKET, REGULATION 63
6 MARKET OVERVIEW 65
6.1 DRIVERS 67
6.1.1 INCREASING INCIDENCES OF CHRONIC AND COMMUNICABLE EYE DISEASES 67
6.1.2 INCREASED CONSUMER AWARENESS FOR LASER TREATMENTS 67
6.1.3 INCREASING ADOPTION OF OUTPATIENT PROCEDURES 68
6.1.4 RISING DEMAND FOR MINIMALLY INVASIVE SURGICAL PROCEDURES 69
6.2 RESTRAINTS 70
6.2.1 HIGH COST OF OPHTHALMOLOGY LASER PROCEDURES 70
6.2.2 STRINGENT REGULATORY POLICIES 70
6.3 OPPORTUNITIES 71
6.3.1 TECHNOLOGICAL ADVANCEMENTS IN OPHTHALMOLOGY 71
6.3.2 EMERGING MARKETS AND GOVERNMENT FUNDING 72
6.4 CHALLENGES 73
6.4.1 LACK OF SKILLED PROFESSIONALS 73
6.4.2 SAFETY CONCERNS 73
7 EUROPE OPHTHALMOLOGY LASERS MARKET, BY PRODUCT 75
7.1 OVERVIEW 76
7.2 EXCIMER LASERS 79
7.2.1 ARF 80
7.2.2 KRF 80
7.2.3 XECL 80
7.2.4 XEFL 80
7.2.5 F2 80
7.2.6 XEBR 80
7.3 FEMTOSECOND LASERS 80
7.3.1 SEMICONDUCTOR LASERS 81
7.3.2 SOLID-STATE BULK LASERS 82
7.3.3 FREQUENCY-CONVERTED SOURCES 82
7.3.4 FIBER LASERS 82
7.3.5 DYE LASERS 82
7.3.6 OTHERS 82
7.4 ND:YAG LASERS 82
7.4.1 ND: YAG LASER AT 1064 NM 83
7.4.2 ND: YAG GREEN LASER AT 532 NM 83
7.5 DIODE LASERS 83
7.6 OTHERS 84
8 EUROPE OPHTHALMOLOGY LASERS MARKET, BY TYPE 85
8.1 OVERVIEW 86
8.2 PHOTOCOAGULATION LASERS 89
8.3 SELECTIVE LASER TRABECULOPLASTY (SLT) 89
8.4 PHOTODISRUPTION LASERS 90
9 EUROPE OPHTHALMOLOGY LASERS MARKET, BY APPLICATION 92
9.1 OVERVIEW 93
9.2 THERAPEUTICS 96
9.2.1 CATARACT REMOVAL 97
9.2.2 GLAUCOMA TREATMENT 97
9.2.3 DIABETIC RETINOPATHY TREATMENT 97
9.2.4 REFRACTIVE ERROR CORRECTION 97
9.2.5 AMD TREATMENT 97
9.2.6 OTHERS 97
9.3 DIAGNOSTICS 98
9.3.1 OPTICAL COHERENCE TOMOGRAPHY (OCT) 99
9.3.2 SCANNING LASER OPHTHALMOSCOPE (SLO) 99
10 EUROPE OPHTHALMOLOGY LASERS MARKET, BY GASES 100
10.1 OVERVIEW 101
10.2 NOBLE GAS 104
10.2.1 ARGON 105
10.2.2 XENON 105
10.2.3 KRYPTON 105
10.3 HALOGEN GAS 105
10.3.1 CHLORINE 106
10.3.2 BROMINE 106
10.3.3 FLOURINE 106
10.4 BUFFER GAS 106
10.4.1 HELIUM 107
10.4.2 NEON 107
10.5 OTHERS 108
11 EUROPE OPHTHALMOLOGY LASERS MARKET, BY END USER 109
11.1 OVERVIEW 110
11.2 HOSPITALS 113
11.3 CLINICS 113
11.4 OTHERS 114
12 EUROPE OPHTHALMOLOGY LASERS MARKET, BY REGION 116
12.1 EUROPE 117
12.1.1 GERMANY 125
12.1.2 FRANCE 129
12.1.3 U.K. 133
12.1.4 ITALY 137
12.1.5 SPAIN 141
12.1.6 RUSSIA 145
12.1.7 TURKEY 149
12.1.8 BELGIUM 153
12.1.9 NETHERLANDS 157
12.1.10 SWITZERLAND 161
12.1.11 REST OF EUROPE 165
13 EUROPE OPHTHALMOLOGY LASERS MARKET: COMPANY LANDSCAPE 166
13.1 COMPANY SHARE ANALYSIS: EUROPE 166
14 SWOT ANALYSIS 167
15 EUROPE OPHTHALMOLOGY LASERS MARKET, CPS 168
15.1 BAUSCH & LOMB INCORPORATED 168
15.1.1 COMPANY SNAPSHOT 168
15.1.2 REVENUE ANALYSIS 168
15.1.3 COMPANY SHARE ANALYSIS 169
15.1.4 PRODUCT PORTFOLIO 169
15.1.5 RECENT DEVELOPMENT 169
15.2 JOHNSON & JOHNSON, INC. 170
15.2.1 COMPANY SNAPSHOT 170
15.2.2 REVENUE ANALYSIS 170
15.2.3 COMPANY SHARE ANALYSIS 171
15.2.4 PRODUCT PORTFOLIO 171
15.2.5 RECENT DEVELOPMENT 171
15.3 ZEISS 172
15.3.1 COMPANY SNAPSHOT 172
15.3.2 REVENUE ANALYSIS 172
15.3.3 COMPANY SHARE ANALYSIS 173
15.3.4 PRODUCT PORTFOLIO 173
15.3.5 RECENT DEVELOPMENT 173
15.4 ALCON 174
15.4.1 COMPANY SNAPSHOT 174
15.4.2 REVENUE ANALYSIS 174
15.4.3 COMPANY SHARE ANALYSIS 175
15.4.4 PRODUCT PORTFOLIO 175
15.4.5 RECENT DEVELOPMENT 175
15.5 NIDEK CO., LTD 176
15.5.1 COMPANY SNAPSHOT 176
15.5.2 REVENUE ANALYSIS 176
15.5.3 COMPANY SHARE ANALYSIS 177
15.5.4 PRODUCT PORTFOLIO 177
15.5.5 RECENT DEVELOPMENT 177
15.6 ARC LASER GMBH 178
15.6.1 COMPANY SNAPSHOT 178
15.6.2 PRODUCT PORTFOLIO 178
15.6.3 RECENT DEVELOPMENT 178
15.7 AUROLAB 179
15.7.1 COMPANY SNAPSHOT 179
15.7.2 PRODUCT PORTFOLIO 179
15.7.3 RECENT DEVELOPMENT 179
15.8 CALMAR LASER 180
15.8.1 COMPANY SNAPSHOT 180
15.8.2 PRODUCT PORTFOLIO 180
15.8.3 RECENT DEVELOPMENT 180
15.9 IRIDEX CORPORATION 181
15.9.1 COMPANY SNAPSHOT 181
15.9.2 REVENUE ANALYSIS 181
15.9.3 PRODUCT PORTFOLIO 182
15.9.4 RECENT DEVELOPMENT 182
15.10 IVIS TECHNOLOGIES 183
15.10.1 COMPANY SNAPSHOT 183
15.10.2 PRODUCT PORTFOLIO 183
15.10.3 RECENT DEVELOPMENT 183
15.11 LENSAR, INC. 184
15.11.1 COMPANY SNAPSHOT 184
15.11.2 REVENUE ANALYSIS 184
15.11.3 PRODUCT PORTFOLIO 185
15.11.4 RECENT DEVELOPMENT 185
15.12 LUMENIS BE LTD. 186
15.12.1 COMPANY SNAPSHOT 186
15.12.2 PRODUCT PORTFOLIO 186
15.12.3 RECENT DEVELOPMENT 186
15.13 LIGHTMED 187
15.13.1 COMPANY SNAPSHOT 187
15.13.2 PRODUCT PORTFOLIO 187
15.13.3 RECENT DEVELOPMENT 187
15.14 MEDA CO., LTD. 188
15.14.1 COMPANY SNAPSHOT 188
15.14.2 PRODUCT PORTFOLIO 188
15.14.3 RECENT DEVELOPMENT 188
15.15 OD-OS 189
15.15.1 COMPANY SNAPSHOT 189
15.15.2 PRODUCT PORTFOLIO 189
15.15.3 RECENT DEVELOPMENT 189
15.16 QUANTEL MEDICAL (A SUBSIDIARY OF LUMIBIRD MEDICAL) 190
15.16.1 COMPANY SNAPSHOT 190
15.16.2 REVENUE ANALYSIS 190
15.16.3 PRODUCT PORTFOLIO 191
15.16.4 RECENT DEVELOPMENT 191
15.17 SCHWIND EYE-TECH-SOLUTIONS 192
15.17.1 COMPANY SNAPSHOT 192
15.17.2 PRODUCT PORTFOLIO 192
15.17.3 RECENT DEVELOPMENT 192
15.18 TOPCON 193
15.18.1 COMPANY SNAPSHOT 193
15.18.2 REVENUE ANALYSIS 193
15.18.3 PRODUCT PORTFOLIO 194
15.18.4 RECENT DEVELOPMENT 194
15.19 ZIEMER OPHTHALMIC SYSTEMS AG 195
15.19.1 COMPANY SNAPSHOT 195
15.19.2 PRODUCT PORTFOLIO 195
15.19.3 RECENT DEVELOPMENT 195
16 QUESTIONNAIRE 196
17 RELATED REPORTS 199

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.